Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis

Official title: Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosi

Sponsor: University of California, Los Angeles
Collaborators: University of Pittsburgh Medical Center, University of Chicago, Bay State Clinical Trials, Inc., Yale University, University of Vermont, University of Southern California
Enrollment: 250 (Estimated)
Study start: 2022-09-30 (Actual)
Primary completion: 2027-09-30 (Estimated)
Study completion: 2027-09-30 (Estimated)
Allocation: N/a
InterventionModel: N/a
Masking: None
PrimaryPurpose: Other

Brief Summary

An observational study to determine if individuals with increased platelet FcyRIIa will have a higher risk of ischemic events.

Determine the impact of platelet FcγRIIa expression on 1-year risk of recurrent stroke in ICAD. (1 year)
The investigators hypothesize that increased platelet FcγRIIa will be associated with a greater risk of ischemic events. Platelet FcγRIIa expression will be quantified in 250 subjects enrolled at 6 sites with stroke or TIA due to 50-99% ICAD to determine impact of FcγRIIa on 1-year risk of recurrent stroke, including clinical events and serial MRI.
Quantify the impact of WSS from CTA CFD on 1-year risk of recurrent stroke in ICAD (1 year)
The investigators hypothesize that high WSS and an elevated post-stenotic oscillatory shear index (OSI) that are stimuli of shear-induced platelet aggregation will confer an increased risk of recurrent ischemic stroke. We will use routinely acquired CTA in 250 subjects enrolled at 6 sites with stroke or TIA due to 50-99% ICAD to quantify the impact of WSS and post-stenotic OSI on 1-year risk of recurrent stroke, including clinical events and serial MRI.
Develop a precision model to determine the risk of recurrent stroke 1 year after index events due to ICAD based on individual FcγRIIa expression and WSS from baseline CTA. (1 year)
The investigators hypothesize that the 1-year recurrent stroke risk associated with high platelet FcγRIIa expression and high WSS will be more than additive.

United States

Ronald Reagan UCLA Medical Center, Los Angeles, United States (Recruiting)
- Ryan Apfel
- David Liebeskind, MD (Principal Investigator)